GNBT TIC,TOC $$$ ~~~ @ ASCO 2013 .The presentation
Post# of 88871
Posted On: 05/30/2013 9:28:08 AM
GNBT TIC,TOC $$$ ~~~ @ ASCO 2013 .The presentation entitled "Booster inoculations of the AE37 peptide vaccine enhance immunological responses in a phase II study", by Eleftheria Anastasopoulou et al, demonstrates that increased immunological responses observed after the initial series of inoculations with AE37 can be further increased over a 24 month period in patients receiving boosters every six months. The AE37 vaccine is a combination of a fragment of the HER2 protein plus a proprietary modification developed by Antigen Express scientists.
ss="MsoNormal"> GNBT TIC,TOC $$$ ~~~ @ ASCO 2013 .The presentation entitled "Booster inoculations of the AE37 peptide vaccine enhance immunological responses in a phase II study", by Eleftheria Anastasopoulou et al, demonstrates that increased immunological responses observed after the initial series of inoculations with AE37 can be further increased over a 24 month period in patients receiving boosters every six months. The AE37 vaccine is a combination of a fragment of the HER2 protein plus a proprietary modification developed by Antigen Express scientists.
oNormal"> GNBT TIC,TOC $$$ ~~~ @ ASCO 2013 .The presentation entitled "Booster inoculations of the AE37 peptide vaccine enhance immunological responses in a phase II study", by Eleftheria Anastasopoulou et al, demonstrates that increased immunological responses observed after the initial series of inoculations with AE37 can be further increased over a 24 month period in patients receiving boosters every six months. The AE37 vaccine is a combination of a fragment of the HER2 protein plus a proprietary modification developed by Antigen Express scientists.
l"> GNBT TIC,TOC $$$ ~~~ @ ASCO 2013 .The presentation entitled "Booster inoculations of the AE37 peptide vaccine enhance immunological responses in a phase II study", by Eleftheria Anastasopoulou et al, demonstrates that increased immunological responses observed after the initial series of inoculations with AE37 can be further increased over a 24 month period in patients receiving boosters every six months. The AE37 vaccine is a combination of a fragment of the HER2 protein plus a proprietary modification developed by Antigen Express scientists.
BT TIC,TOC $$$ ~~~ @ ASCO 2013 .The presentation entitled "Booster inoculations of the AE37 peptide vaccine enhance immunological responses in a phase II study", by Eleftheria Anastasopoulou et al, demonstrates that increased immunological responses observed after the initial series of inoculations with AE37 can be further increased over a 24 month period in patients receiving boosters every six months. The AE37 vaccine is a combination of a fragment of the HER2 protein plus a proprietary modification developed by Antigen Express scientists.
,TOC $$$ ~~~ @ ASCO 2013 .The presentation entitled "Booster inoculations of the AE37 peptide vaccine enhance immunological responses in a phase II study", by Eleftheria Anastasopoulou et al, demonstrates that increased immunological responses observed after the initial series of inoculations with AE37 can be further increased over a 24 month period in patients receiving boosters every six months. The AE37 vaccine is a combination of a fragment of the HER2 protein plus a proprietary modification developed by Antigen Express scientists.
$$ ~~~ @ ASCO 2013 .The presentation entitled "Booster inoculations of the AE37 peptide vaccine enhance immunological responses in a phase II study", by Eleftheria Anastasopoulou et al, demonstrates that increased immunological responses observed after the initial series of inoculations with AE37 can be further increased over a 24 month period in patients receiving boosters every six months. The AE37 vaccine is a combination of a fragment of the HER2 protein plus a proprietary modification developed by Antigen Express scientists.
@ ASCO 2013 .The presentation entitled "Booster inoculations of the AE37 peptide vaccine enhance immunological responses in a phase II study", by Eleftheria Anastasopoulou et al, demonstrates that increased immunological responses observed after the initial series of inoculations with AE37 can be further increased over a 24 month period in patients receiving boosters every six months. The AE37 vaccine is a combination of a fragment of the HER2 protein plus a proprietary modification developed by Antigen Express scientists.
style="font-size: 11.5pt; line-height: 115%; font-family: Arial, sans-serif; background-color: #e6e8fa; background-position: initial initial; background-repeat: initial initial;"> @ ASCO 2013 .The presentation entitled "Booster inoculations of the AE37 peptide vaccine enhance immunological responses in a phase II study", by Eleftheria Anastasopoulou et al, demonstrates that increased immunological responses observed after the initial series of inoculations with AE37 can be further increased over a 24 month period in patients receiving boosters every six months. The AE37 vaccine is a combination of a fragment of the HER2 protein plus a proprietary modification developed by Antigen Express scientists.
"font-size: 11.5pt; line-height: 115%; font-family: Arial, sans-serif; background-color: #e6e8fa; background-position: initial initial; background-repeat: initial initial;"> @ ASCO 2013 .The presentation entitled "Booster inoculations of the AE37 peptide vaccine enhance immunological responses in a phase II study", by Eleftheria Anastasopoulou et al, demonstrates that increased immunological responses observed after the initial series of inoculations with AE37 can be further increased over a 24 month period in patients receiving boosters every six months. The AE37 vaccine is a combination of a fragment of the HER2 protein plus a proprietary modification developed by Antigen Express scientists.
size: 11.5pt; line-height: 115%; font-family: Arial, sans-serif; background-color: #e6e8fa; background-position: initial initial; background-repeat: initial initial;"> @ ASCO 2013 .The presentation entitled "Booster inoculations of the AE37 peptide vaccine enhance immunological responses in a phase II study", by Eleftheria Anastasopoulou et al, demonstrates that increased immunological responses observed after the initial series of inoculations with AE37 can be further increased over a 24 month period in patients receiving boosters every six months. The AE37 vaccine is a combination of a fragment of the HER2 protein plus a proprietary modification developed by Antigen Express scientists.
11.5pt; line-height: 115%; font-family: Arial, sans-serif; background-color: #e6e8fa; background-position: initial initial; background-repeat: initial initial;"> @ ASCO 2013 .The presentation entitled "Booster inoculations of the AE37 peptide vaccine enhance immunological responses in a phase II study", by Eleftheria Anastasopoulou et al, demonstrates that increased immunological responses observed after the initial series of inoculations with AE37 can be further increased over a 24 month period in patients receiving boosters every six months. The AE37 vaccine is a combination of a fragment of the HER2 protein plus a proprietary modification developed by Antigen Express scientists.
; line-height: 115%; font-family: Arial, sans-serif; background-color: #e6e8fa; background-position: initial initial; background-repeat: initial initial;"> @ ASCO 2013 .The presentation entitled "Booster inoculations of the AE37 peptide vaccine enhance immunological responses in a phase II study", by Eleftheria Anastasopoulou et al, demonstrates that increased immunological responses observed after the initial series of inoculations with AE37 can be further increased over a 24 month period in patients receiving boosters every six months. The AE37 vaccine is a combination of a fragment of the HER2 protein plus a proprietary modification developed by Antigen Express scientists.
-height: 115%; font-family: Arial, sans-serif; background-color: #e6e8fa; background-position: initial initial; background-repeat: initial initial;"> @ ASCO 2013 .The presentation entitled "Booster inoculations of the AE37 peptide vaccine enhance immunological responses in a phase II study", by Eleftheria Anastasopoulou et al, demonstrates that increased immunological responses observed after the initial series of inoculations with AE37 can be further increased over a 24 month period in patients receiving boosters every six months. The AE37 vaccine is a combination of a fragment of the HER2 protein plus a proprietary modification developed by Antigen Express scientists.
t: 115%; font-family: Arial, sans-serif; background-color: #e6e8fa; background-position: initial initial; background-repeat: initial initial;"> @ ASCO 2013 .The presentation entitled "Booster inoculations of the AE37 peptide vaccine enhance immunological responses in a phase II study", by Eleftheria Anastasopoulou et al, demonstrates that increased immunological responses observed after the initial series of inoculations with AE37 can be further increased over a 24 month period in patients receiving boosters every six months. The AE37 vaccine is a combination of a fragment of the HER2 protein plus a proprietary modification developed by Antigen Express scientists.
%; font-family: Arial, sans-serif; background-color: #e6e8fa; background-position: initial initial; background-repeat: initial initial;"> @ ASCO 2013 .The presentation entitled "Booster inoculations of the AE37 peptide vaccine enhance immunological responses in a phase II study", by Eleftheria Anastasopoulou et al, demonstrates that increased immunological responses observed after the initial series of inoculations with AE37 can be further increased over a 24 month period in patients receiving boosters every six months. The AE37 vaccine is a combination of a fragment of the HER2 protein plus a proprietary modification developed by Antigen Express scientists.
t-family: Arial, sans-serif; background-color: #e6e8fa; background-position: initial initial; background-repeat: initial initial;"> @ ASCO 2013 .The presentation entitled "Booster inoculations of the AE37 peptide vaccine enhance immunological responses in a phase II study", by Eleftheria Anastasopoulou et al, demonstrates that increased immunological responses observed after the initial series of inoculations with AE37 can be further increased over a 24 month period in patients receiving boosters every six months. The AE37 vaccine is a combination of a fragment of the HER2 protein plus a proprietary modification developed by Antigen Express scientists.
ly: Arial, sans-serif; background-color: #e6e8fa; background-position: initial initial; background-repeat: initial initial;"> @ ASCO 2013 .The presentation entitled "Booster inoculations of the AE37 peptide vaccine enhance immunological responses in a phase II study", by Eleftheria Anastasopoulou et al, demonstrates that increased immunological responses observed after the initial series of inoculations with AE37 can be further increased over a 24 month period in patients receiving boosters every six months. The AE37 vaccine is a combination of a fragment of the HER2 protein plus a proprietary modification developed by Antigen Express scientists.
ial, sans-serif; background-color: #e6e8fa; background-position: initial initial; background-repeat: initial initial;"> @ ASCO 2013 .The presentation entitled "Booster inoculations of the AE37 peptide vaccine enhance immunological responses in a phase II study", by Eleftheria Anastasopoulou et al, demonstrates that increased immunological responses observed after the initial series of inoculations with AE37 can be further increased over a 24 month period in patients receiving boosters every six months. The AE37 vaccine is a combination of a fragment of the HER2 protein plus a proprietary modification developed by Antigen Express scientists.
ans-serif; background-color: #e6e8fa; background-position: initial initial; background-repeat: initial initial;"> @ ASCO 2013 .The presentation entitled "Booster inoculations of the AE37 peptide vaccine enhance immunological responses in a phase II study", by Eleftheria Anastasopoulou et al, demonstrates that increased immunological responses observed after the initial series of inoculations with AE37 can be further increased over a 24 month period in patients receiving boosters every six months. The AE37 vaccine is a combination of a fragment of the HER2 protein plus a proprietary modification developed by Antigen Express scientists.
rif; background-color: #e6e8fa; background-position: initial initial; background-repeat: initial initial;"> @ ASCO 2013 .The presentation entitled "Booster inoculations of the AE37 peptide vaccine enhance immunological responses in a phase II study", by Eleftheria Anastasopoulou et al, demonstrates that increased immunological responses observed after the initial series of inoculations with AE37 can be further increased over a 24 month period in patients receiving boosters every six months. The AE37 vaccine is a combination of a fragment of the HER2 protein plus a proprietary modification developed by Antigen Express scientists.
ackground-color: #e6e8fa; background-position: initial initial; background-repeat: initial initial;"> @ ASCO 2013 .The presentation entitled "Booster inoculations of the AE37 peptide vaccine enhance immunological responses in a phase II study", by Eleftheria Anastasopoulou et al, demonstrates that increased immunological responses observed after the initial series of inoculations with AE37 can be further increased over a 24 month period in patients receiving boosters every six months. The AE37 vaccine is a combination of a fragment of the HER2 protein plus a proprietary modification developed by Antigen Express scientists.
und-color: #e6e8fa; background-position: initial initial; background-repeat: initial initial;"> @ ASCO 2013 .The presentation entitled "Booster inoculations of the AE37 peptide vaccine enhance immunological responses in a phase II study", by Eleftheria Anastasopoulou et al, demonstrates that increased immunological responses observed after the initial series of inoculations with AE37 can be further increased over a 24 month period in patients receiving boosters every six months. The AE37 vaccine is a combination of a fragment of the HER2 protein plus a proprietary modification developed by Antigen Express scientists.
lor: #e6e8fa; background-position: initial initial; background-repeat: initial initial;"> @ ASCO 2013 .The presentation entitled "Booster inoculations of the AE37 peptide vaccine enhance immunological responses in a phase II study", by Eleftheria Anastasopoulou et al, demonstrates that increased immunological responses observed after the initial series of inoculations with AE37 can be further increased over a 24 month period in patients receiving boosters every six months. The AE37 vaccine is a combination of a fragment of the HER2 protein plus a proprietary modification developed by Antigen Express scientists.
e6e8fa; background-position: initial initial; background-repeat: initial initial;"> @ ASCO 2013 .The presentation entitled "Booster inoculations of the AE37 peptide vaccine enhance immunological responses in a phase II study", by Eleftheria Anastasopoulou et al, demonstrates that increased immunological responses observed after the initial series of inoculations with AE37 can be further increased over a 24 month period in patients receiving boosters every six months. The AE37 vaccine is a combination of a fragment of the HER2 protein plus a proprietary modification developed by Antigen Express scientists.
; background-position: initial initial; background-repeat: initial initial;"> @ ASCO 2013 .The presentation entitled "Booster inoculations of the AE37 peptide vaccine enhance immunological responses in a phase II study", by Eleftheria Anastasopoulou et al, demonstrates that increased immunological responses observed after the initial series of inoculations with AE37 can be further increased over a 24 month period in patients receiving boosters every six months. The AE37 vaccine is a combination of a fragment of the HER2 protein plus a proprietary modification developed by Antigen Express scientists.
ground-position: initial initial; background-repeat: initial initial;"> @ ASCO 2013 .The presentation entitled "Booster inoculations of the AE37 peptide vaccine enhance immunological responses in a phase II study", by Eleftheria Anastasopoulou et al, demonstrates that increased immunological responses observed after the initial series of inoculations with AE37 can be further increased over a 24 month period in patients receiving boosters every six months. The AE37 vaccine is a combination of a fragment of the HER2 protein plus a proprietary modification developed by Antigen Express scientists.
-position: initial initial; background-repeat: initial initial;"> @ ASCO 2013 .The presentation entitled "Booster inoculations of the AE37 peptide vaccine enhance immunological responses in a phase II study", by Eleftheria Anastasopoulou et al, demonstrates that increased immunological responses observed after the initial series of inoculations with AE37 can be further increased over a 24 month period in patients receiving boosters every six months. The AE37 vaccine is a combination of a fragment of the HER2 protein plus a proprietary modification developed by Antigen Express scientists.
ion: initial initial; background-repeat: initial initial;"> @ ASCO 2013 .The presentation entitled "Booster inoculations of the AE37 peptide vaccine enhance immunological responses in a phase II study", by Eleftheria Anastasopoulou et al, demonstrates that increased immunological responses observed after the initial series of inoculations with AE37 can be further increased over a 24 month period in patients receiving boosters every six months. The AE37 vaccine is a combination of a fragment of the HER2 protein plus a proprietary modification developed by Antigen Express scientists.
nitial initial; background-repeat: initial initial;"> @ ASCO 2013 .The presentation entitled "Booster inoculations of the AE37 peptide vaccine enhance immunological responses in a phase II study", by Eleftheria Anastasopoulou et al, demonstrates that increased immunological responses observed after the initial series of inoculations with AE37 can be further increased over a 24 month period in patients receiving boosters every six months. The AE37 vaccine is a combination of a fragment of the HER2 protein plus a proprietary modification developed by Antigen Express scientists.
initial; background-repeat: initial initial;"> @ ASCO 2013 .The presentation entitled "Booster inoculations of the AE37 peptide vaccine enhance immunological responses in a phase II study", by Eleftheria Anastasopoulou et al, demonstrates that increased immunological responses observed after the initial series of inoculations with AE37 can be further increased over a 24 month period in patients receiving boosters every six months. The AE37 vaccine is a combination of a fragment of the HER2 protein plus a proprietary modification developed by Antigen Express scientists.
al; background-repeat: initial initial;"> @ ASCO 2013 .The presentation entitled "Booster inoculations of the AE37 peptide vaccine enhance immunological responses in a phase II study", by Eleftheria Anastasopoulou et al, demonstrates that increased immunological responses observed after the initial series of inoculations with AE37 can be further increased over a 24 month period in patients receiving boosters every six months. The AE37 vaccine is a combination of a fragment of the HER2 protein plus a proprietary modification developed by Antigen Express scientists.
ckground-repeat: initial initial;"> @ ASCO 2013 .The presentation entitled "Booster inoculations of the AE37 peptide vaccine enhance immunological responses in a phase II study", by Eleftheria Anastasopoulou et al, demonstrates that increased immunological responses observed after the initial series of inoculations with AE37 can be further increased over a 24 month period in patients receiving boosters every six months. The AE37 vaccine is a combination of a fragment of the HER2 protein plus a proprietary modification developed by Antigen Express scientists.
nd-repeat: initial initial;"> @ ASCO 2013 .The presentation entitled "Booster inoculations of the AE37 peptide vaccine enhance immunological responses in a phase II study", by Eleftheria Anastasopoulou et al, demonstrates that increased immunological responses observed after the initial series of inoculations with AE37 can be further increased over a 24 month period in patients receiving boosters every six months. The AE37 vaccine is a combination of a fragment of the HER2 protein plus a proprietary modification developed by Antigen Express scientists.
eat: initial initial;"> @ ASCO 2013 .The presentation entitled "Booster inoculations of the AE37 peptide vaccine enhance immunological responses in a phase II study", by Eleftheria Anastasopoulou et al, demonstrates that increased immunological responses observed after the initial series of inoculations with AE37 can be further increased over a 24 month period in patients receiving boosters every six months. The AE37 vaccine is a combination of a fragment of the HER2 protein plus a proprietary modification developed by Antigen Express scientists.
nitial initial;"> @ ASCO 2013 .The presentation entitled "Booster inoculations of the AE37 peptide vaccine enhance immunological responses in a phase II study", by Eleftheria Anastasopoulou et al, demonstrates that increased immunological responses observed after the initial series of inoculations with AE37 can be further increased over a 24 month period in patients receiving boosters every six months. The AE37 vaccine is a combination of a fragment of the HER2 protein plus a proprietary modification developed by Antigen Express scientists.
initial;"> @ ASCO 2013 .The presentation entitled "Booster inoculations of the AE37 peptide vaccine enhance immunological responses in a phase II study", by Eleftheria Anastasopoulou et al, demonstrates that increased immunological responses observed after the initial series of inoculations with AE37 can be further increased over a 24 month period in patients receiving boosters every six months. The AE37 vaccine is a combination of a fragment of the HER2 protein plus a proprietary modification developed by Antigen Express scientists.
al;"> @ ASCO 2013 .The presentation entitled "Booster inoculations of the AE37 peptide vaccine enhance immunological responses in a phase II study", by Eleftheria Anastasopoulou et al, demonstrates that increased immunological responses observed after the initial series of inoculations with AE37 can be further increased over a 24 month period in patients receiving boosters every six months. The AE37 vaccine is a combination of a fragment of the HER2 protein plus a proprietary modification developed by Antigen Express scientists.
@ ASCO 2013 .The presentation entitled "Booster inoculations of the AE37 peptide vaccine enhance immunological responses in a phase II study", by Eleftheria Anastasopoulou et al, demonstrates that increased immunological responses observed after the initial series of inoculations with AE37 can be further increased over a 24 month period in patients receiving boosters every six months. The AE37 vaccine is a combination of a fragment of the HER2 protein plus a proprietary modification developed by Antigen Express scientists.
O 2013 .The presentation entitled "Booster inoculations of the AE37 peptide vaccine enhance immunological responses in a phase II study", by Eleftheria Anastasopoulou et al, demonstrates that increased immunological responses observed after the initial series of inoculations with AE37 can be further increased over a 24 month period in patients receiving boosters every six months. The AE37 vaccine is a combination of a fragment of the HER2 protein plus a proprietary modification developed by Antigen Express scientists.
.The presentation entitled "Booster inoculations of the AE37 peptide vaccine enhance immunological responses in a phase II study", by Eleftheria Anastasopoulou et al, demonstrates that increased immunological responses observed after the initial series of inoculations with AE37 can be further increased over a 24 month period in patients receiving boosters every six months. The AE37 vaccine is a combination of a fragment of the HER2 protein plus a proprietary modification developed by Antigen Express scientists.
span> presentation entitled "Booster inoculations of the AE37 peptide vaccine enhance immunological responses in a phase II study", by Eleftheria Anastasopoulou et al, demonstrates that increased immunological responses observed after the initial series of inoculations with AE37 can be further increased over a 24 month period in patients receiving boosters every six months. The AE37 vaccine is a combination of a fragment of the HER2 protein plus a proprietary modification developed by Antigen Express scientists.
presentation entitled "Booster inoculations of the AE37 peptide vaccine enhance immunological responses in a phase II study", by Eleftheria Anastasopoulou et al, demonstrates that increased immunological responses observed after the initial series of inoculations with AE37 can be further increased over a 24 month period in patients receiving boosters every six months. The AE37 vaccine is a combination of a fragment of the HER2 protein plus a proprietary modification developed by Antigen Express scientists.
an> presentation entitled "Booster inoculations of the AE37 peptide vaccine enhance immunological responses in a phase II study", by Eleftheria Anastasopoulou et al, demonstrates that increased immunological responses observed after the initial series of inoculations with AE37 can be further increased over a 24 month period in patients receiving boosters every six months. The AE37 vaccine is a combination of a fragment of the HER2 protein plus a proprietary modification developed by Antigen Express scientists.
/span> presentation entitled "Booster inoculations of the AE37 peptide vaccine enhance immunological responses in a phase II study", by Eleftheria Anastasopoulou et al, demonstrates that increased immunological responses observed after the initial series of inoculations with AE37 can be further increased over a 24 month period in patients receiving boosters every six months. The AE37 vaccine is a combination of a fragment of the HER2 protein plus a proprietary modification developed by Antigen Express scientists.
presentation entitled "Booster inoculations of the AE37 peptide vaccine enhance immunological responses in a phase II study", by Eleftheria Anastasopoulou et al, demonstrates that increased immunological responses observed after the initial series of inoculations with AE37 can be further increased over a 24 month period in patients receiving boosters every six months. The AE37 vaccine is a combination of a fragment of the HER2 protein plus a proprietary modification developed by Antigen Express scientists.
l="nofollow" rel="nofollow" href="
ss="MsoNormal"> GNBT TIC,TOC $$$ ~~~ @ ASCO 2013 .The presentation entitled "Booster inoculations of the AE37 peptide vaccine enhance immunological responses in a phase II study", by Eleftheria Anastasopoulou et al, demonstrates that increased immunological responses observed after the initial series of inoculations with AE37 can be further increased over a 24 month period in patients receiving boosters every six months. The AE37 vaccine is a combination of a fragment of the HER2 protein plus a proprietary modification developed by Antigen Express scientists.
oNormal"> GNBT TIC,TOC $$$ ~~~ @ ASCO 2013 .The presentation entitled "Booster inoculations of the AE37 peptide vaccine enhance immunological responses in a phase II study", by Eleftheria Anastasopoulou et al, demonstrates that increased immunological responses observed after the initial series of inoculations with AE37 can be further increased over a 24 month period in patients receiving boosters every six months. The AE37 vaccine is a combination of a fragment of the HER2 protein plus a proprietary modification developed by Antigen Express scientists.
l"> GNBT TIC,TOC $$$ ~~~ @ ASCO 2013 .The presentation entitled "Booster inoculations of the AE37 peptide vaccine enhance immunological responses in a phase II study", by Eleftheria Anastasopoulou et al, demonstrates that increased immunological responses observed after the initial series of inoculations with AE37 can be further increased over a 24 month period in patients receiving boosters every six months. The AE37 vaccine is a combination of a fragment of the HER2 protein plus a proprietary modification developed by Antigen Express scientists.
BT TIC,TOC $$$ ~~~ @ ASCO 2013 .The presentation entitled "Booster inoculations of the AE37 peptide vaccine enhance immunological responses in a phase II study", by Eleftheria Anastasopoulou et al, demonstrates that increased immunological responses observed after the initial series of inoculations with AE37 can be further increased over a 24 month period in patients receiving boosters every six months. The AE37 vaccine is a combination of a fragment of the HER2 protein plus a proprietary modification developed by Antigen Express scientists.
,TOC $$$ ~~~ @ ASCO 2013 .The presentation entitled "Booster inoculations of the AE37 peptide vaccine enhance immunological responses in a phase II study", by Eleftheria Anastasopoulou et al, demonstrates that increased immunological responses observed after the initial series of inoculations with AE37 can be further increased over a 24 month period in patients receiving boosters every six months. The AE37 vaccine is a combination of a fragment of the HER2 protein plus a proprietary modification developed by Antigen Express scientists.
$$ ~~~ @ ASCO 2013 .The presentation entitled "Booster inoculations of the AE37 peptide vaccine enhance immunological responses in a phase II study", by Eleftheria Anastasopoulou et al, demonstrates that increased immunological responses observed after the initial series of inoculations with AE37 can be further increased over a 24 month period in patients receiving boosters every six months. The AE37 vaccine is a combination of a fragment of the HER2 protein plus a proprietary modification developed by Antigen Express scientists.
@ ASCO 2013 .The presentation entitled "Booster inoculations of the AE37 peptide vaccine enhance immunological responses in a phase II study", by Eleftheria Anastasopoulou et al, demonstrates that increased immunological responses observed after the initial series of inoculations with AE37 can be further increased over a 24 month period in patients receiving boosters every six months. The AE37 vaccine is a combination of a fragment of the HER2 protein plus a proprietary modification developed by Antigen Express scientists.
style="font-size: 11.5pt; line-height: 115%; font-family: Arial, sans-serif; background-color: #e6e8fa; background-position: initial initial; background-repeat: initial initial;"> @ ASCO 2013 .The presentation entitled "Booster inoculations of the AE37 peptide vaccine enhance immunological responses in a phase II study", by Eleftheria Anastasopoulou et al, demonstrates that increased immunological responses observed after the initial series of inoculations with AE37 can be further increased over a 24 month period in patients receiving boosters every six months. The AE37 vaccine is a combination of a fragment of the HER2 protein plus a proprietary modification developed by Antigen Express scientists.
"font-size: 11.5pt; line-height: 115%; font-family: Arial, sans-serif; background-color: #e6e8fa; background-position: initial initial; background-repeat: initial initial;"> @ ASCO 2013 .The presentation entitled "Booster inoculations of the AE37 peptide vaccine enhance immunological responses in a phase II study", by Eleftheria Anastasopoulou et al, demonstrates that increased immunological responses observed after the initial series of inoculations with AE37 can be further increased over a 24 month period in patients receiving boosters every six months. The AE37 vaccine is a combination of a fragment of the HER2 protein plus a proprietary modification developed by Antigen Express scientists.
size: 11.5pt; line-height: 115%; font-family: Arial, sans-serif; background-color: #e6e8fa; background-position: initial initial; background-repeat: initial initial;"> @ ASCO 2013 .The presentation entitled "Booster inoculations of the AE37 peptide vaccine enhance immunological responses in a phase II study", by Eleftheria Anastasopoulou et al, demonstrates that increased immunological responses observed after the initial series of inoculations with AE37 can be further increased over a 24 month period in patients receiving boosters every six months. The AE37 vaccine is a combination of a fragment of the HER2 protein plus a proprietary modification developed by Antigen Express scientists.
11.5pt; line-height: 115%; font-family: Arial, sans-serif; background-color: #e6e8fa; background-position: initial initial; background-repeat: initial initial;"> @ ASCO 2013 .The presentation entitled "Booster inoculations of the AE37 peptide vaccine enhance immunological responses in a phase II study", by Eleftheria Anastasopoulou et al, demonstrates that increased immunological responses observed after the initial series of inoculations with AE37 can be further increased over a 24 month period in patients receiving boosters every six months. The AE37 vaccine is a combination of a fragment of the HER2 protein plus a proprietary modification developed by Antigen Express scientists.
; line-height: 115%; font-family: Arial, sans-serif; background-color: #e6e8fa; background-position: initial initial; background-repeat: initial initial;"> @ ASCO 2013 .The presentation entitled "Booster inoculations of the AE37 peptide vaccine enhance immunological responses in a phase II study", by Eleftheria Anastasopoulou et al, demonstrates that increased immunological responses observed after the initial series of inoculations with AE37 can be further increased over a 24 month period in patients receiving boosters every six months. The AE37 vaccine is a combination of a fragment of the HER2 protein plus a proprietary modification developed by Antigen Express scientists.
-height: 115%; font-family: Arial, sans-serif; background-color: #e6e8fa; background-position: initial initial; background-repeat: initial initial;"> @ ASCO 2013 .The presentation entitled "Booster inoculations of the AE37 peptide vaccine enhance immunological responses in a phase II study", by Eleftheria Anastasopoulou et al, demonstrates that increased immunological responses observed after the initial series of inoculations with AE37 can be further increased over a 24 month period in patients receiving boosters every six months. The AE37 vaccine is a combination of a fragment of the HER2 protein plus a proprietary modification developed by Antigen Express scientists.
t: 115%; font-family: Arial, sans-serif; background-color: #e6e8fa; background-position: initial initial; background-repeat: initial initial;"> @ ASCO 2013 .The presentation entitled "Booster inoculations of the AE37 peptide vaccine enhance immunological responses in a phase II study", by Eleftheria Anastasopoulou et al, demonstrates that increased immunological responses observed after the initial series of inoculations with AE37 can be further increased over a 24 month period in patients receiving boosters every six months. The AE37 vaccine is a combination of a fragment of the HER2 protein plus a proprietary modification developed by Antigen Express scientists.
%; font-family: Arial, sans-serif; background-color: #e6e8fa; background-position: initial initial; background-repeat: initial initial;"> @ ASCO 2013 .The presentation entitled "Booster inoculations of the AE37 peptide vaccine enhance immunological responses in a phase II study", by Eleftheria Anastasopoulou et al, demonstrates that increased immunological responses observed after the initial series of inoculations with AE37 can be further increased over a 24 month period in patients receiving boosters every six months. The AE37 vaccine is a combination of a fragment of the HER2 protein plus a proprietary modification developed by Antigen Express scientists.
t-family: Arial, sans-serif; background-color: #e6e8fa; background-position: initial initial; background-repeat: initial initial;"> @ ASCO 2013 .The presentation entitled "Booster inoculations of the AE37 peptide vaccine enhance immunological responses in a phase II study", by Eleftheria Anastasopoulou et al, demonstrates that increased immunological responses observed after the initial series of inoculations with AE37 can be further increased over a 24 month period in patients receiving boosters every six months. The AE37 vaccine is a combination of a fragment of the HER2 protein plus a proprietary modification developed by Antigen Express scientists.
ly: Arial, sans-serif; background-color: #e6e8fa; background-position: initial initial; background-repeat: initial initial;"> @ ASCO 2013 .The presentation entitled "Booster inoculations of the AE37 peptide vaccine enhance immunological responses in a phase II study", by Eleftheria Anastasopoulou et al, demonstrates that increased immunological responses observed after the initial series of inoculations with AE37 can be further increased over a 24 month period in patients receiving boosters every six months. The AE37 vaccine is a combination of a fragment of the HER2 protein plus a proprietary modification developed by Antigen Express scientists.
ial, sans-serif; background-color: #e6e8fa; background-position: initial initial; background-repeat: initial initial;"> @ ASCO 2013 .The presentation entitled "Booster inoculations of the AE37 peptide vaccine enhance immunological responses in a phase II study", by Eleftheria Anastasopoulou et al, demonstrates that increased immunological responses observed after the initial series of inoculations with AE37 can be further increased over a 24 month period in patients receiving boosters every six months. The AE37 vaccine is a combination of a fragment of the HER2 protein plus a proprietary modification developed by Antigen Express scientists.
ans-serif; background-color: #e6e8fa; background-position: initial initial; background-repeat: initial initial;"> @ ASCO 2013 .The presentation entitled "Booster inoculations of the AE37 peptide vaccine enhance immunological responses in a phase II study", by Eleftheria Anastasopoulou et al, demonstrates that increased immunological responses observed after the initial series of inoculations with AE37 can be further increased over a 24 month period in patients receiving boosters every six months. The AE37 vaccine is a combination of a fragment of the HER2 protein plus a proprietary modification developed by Antigen Express scientists.
rif; background-color: #e6e8fa; background-position: initial initial; background-repeat: initial initial;"> @ ASCO 2013 .The presentation entitled "Booster inoculations of the AE37 peptide vaccine enhance immunological responses in a phase II study", by Eleftheria Anastasopoulou et al, demonstrates that increased immunological responses observed after the initial series of inoculations with AE37 can be further increased over a 24 month period in patients receiving boosters every six months. The AE37 vaccine is a combination of a fragment of the HER2 protein plus a proprietary modification developed by Antigen Express scientists.
ackground-color: #e6e8fa; background-position: initial initial; background-repeat: initial initial;"> @ ASCO 2013 .The presentation entitled "Booster inoculations of the AE37 peptide vaccine enhance immunological responses in a phase II study", by Eleftheria Anastasopoulou et al, demonstrates that increased immunological responses observed after the initial series of inoculations with AE37 can be further increased over a 24 month period in patients receiving boosters every six months. The AE37 vaccine is a combination of a fragment of the HER2 protein plus a proprietary modification developed by Antigen Express scientists.
und-color: #e6e8fa; background-position: initial initial; background-repeat: initial initial;"> @ ASCO 2013 .The presentation entitled "Booster inoculations of the AE37 peptide vaccine enhance immunological responses in a phase II study", by Eleftheria Anastasopoulou et al, demonstrates that increased immunological responses observed after the initial series of inoculations with AE37 can be further increased over a 24 month period in patients receiving boosters every six months. The AE37 vaccine is a combination of a fragment of the HER2 protein plus a proprietary modification developed by Antigen Express scientists.
lor: #e6e8fa; background-position: initial initial; background-repeat: initial initial;"> @ ASCO 2013 .The presentation entitled "Booster inoculations of the AE37 peptide vaccine enhance immunological responses in a phase II study", by Eleftheria Anastasopoulou et al, demonstrates that increased immunological responses observed after the initial series of inoculations with AE37 can be further increased over a 24 month period in patients receiving boosters every six months. The AE37 vaccine is a combination of a fragment of the HER2 protein plus a proprietary modification developed by Antigen Express scientists.
e6e8fa; background-position: initial initial; background-repeat: initial initial;"> @ ASCO 2013 .The presentation entitled "Booster inoculations of the AE37 peptide vaccine enhance immunological responses in a phase II study", by Eleftheria Anastasopoulou et al, demonstrates that increased immunological responses observed after the initial series of inoculations with AE37 can be further increased over a 24 month period in patients receiving boosters every six months. The AE37 vaccine is a combination of a fragment of the HER2 protein plus a proprietary modification developed by Antigen Express scientists.
; background-position: initial initial; background-repeat: initial initial;"> @ ASCO 2013 .The presentation entitled "Booster inoculations of the AE37 peptide vaccine enhance immunological responses in a phase II study", by Eleftheria Anastasopoulou et al, demonstrates that increased immunological responses observed after the initial series of inoculations with AE37 can be further increased over a 24 month period in patients receiving boosters every six months. The AE37 vaccine is a combination of a fragment of the HER2 protein plus a proprietary modification developed by Antigen Express scientists.
ground-position: initial initial; background-repeat: initial initial;"> @ ASCO 2013 .The presentation entitled "Booster inoculations of the AE37 peptide vaccine enhance immunological responses in a phase II study", by Eleftheria Anastasopoulou et al, demonstrates that increased immunological responses observed after the initial series of inoculations with AE37 can be further increased over a 24 month period in patients receiving boosters every six months. The AE37 vaccine is a combination of a fragment of the HER2 protein plus a proprietary modification developed by Antigen Express scientists.
-position: initial initial; background-repeat: initial initial;"> @ ASCO 2013 .The presentation entitled "Booster inoculations of the AE37 peptide vaccine enhance immunological responses in a phase II study", by Eleftheria Anastasopoulou et al, demonstrates that increased immunological responses observed after the initial series of inoculations with AE37 can be further increased over a 24 month period in patients receiving boosters every six months. The AE37 vaccine is a combination of a fragment of the HER2 protein plus a proprietary modification developed by Antigen Express scientists.
ion: initial initial; background-repeat: initial initial;"> @ ASCO 2013 .The presentation entitled "Booster inoculations of the AE37 peptide vaccine enhance immunological responses in a phase II study", by Eleftheria Anastasopoulou et al, demonstrates that increased immunological responses observed after the initial series of inoculations with AE37 can be further increased over a 24 month period in patients receiving boosters every six months. The AE37 vaccine is a combination of a fragment of the HER2 protein plus a proprietary modification developed by Antigen Express scientists.
nitial initial; background-repeat: initial initial;"> @ ASCO 2013 .The presentation entitled "Booster inoculations of the AE37 peptide vaccine enhance immunological responses in a phase II study", by Eleftheria Anastasopoulou et al, demonstrates that increased immunological responses observed after the initial series of inoculations with AE37 can be further increased over a 24 month period in patients receiving boosters every six months. The AE37 vaccine is a combination of a fragment of the HER2 protein plus a proprietary modification developed by Antigen Express scientists.
initial; background-repeat: initial initial;"> @ ASCO 2013 .The presentation entitled "Booster inoculations of the AE37 peptide vaccine enhance immunological responses in a phase II study", by Eleftheria Anastasopoulou et al, demonstrates that increased immunological responses observed after the initial series of inoculations with AE37 can be further increased over a 24 month period in patients receiving boosters every six months. The AE37 vaccine is a combination of a fragment of the HER2 protein plus a proprietary modification developed by Antigen Express scientists.
al; background-repeat: initial initial;"> @ ASCO 2013 .The presentation entitled "Booster inoculations of the AE37 peptide vaccine enhance immunological responses in a phase II study", by Eleftheria Anastasopoulou et al, demonstrates that increased immunological responses observed after the initial series of inoculations with AE37 can be further increased over a 24 month period in patients receiving boosters every six months. The AE37 vaccine is a combination of a fragment of the HER2 protein plus a proprietary modification developed by Antigen Express scientists.
ckground-repeat: initial initial;"> @ ASCO 2013 .The presentation entitled "Booster inoculations of the AE37 peptide vaccine enhance immunological responses in a phase II study", by Eleftheria Anastasopoulou et al, demonstrates that increased immunological responses observed after the initial series of inoculations with AE37 can be further increased over a 24 month period in patients receiving boosters every six months. The AE37 vaccine is a combination of a fragment of the HER2 protein plus a proprietary modification developed by Antigen Express scientists.
nd-repeat: initial initial;"> @ ASCO 2013 .The presentation entitled "Booster inoculations of the AE37 peptide vaccine enhance immunological responses in a phase II study", by Eleftheria Anastasopoulou et al, demonstrates that increased immunological responses observed after the initial series of inoculations with AE37 can be further increased over a 24 month period in patients receiving boosters every six months. The AE37 vaccine is a combination of a fragment of the HER2 protein plus a proprietary modification developed by Antigen Express scientists.
eat: initial initial;"> @ ASCO 2013 .The presentation entitled "Booster inoculations of the AE37 peptide vaccine enhance immunological responses in a phase II study", by Eleftheria Anastasopoulou et al, demonstrates that increased immunological responses observed after the initial series of inoculations with AE37 can be further increased over a 24 month period in patients receiving boosters every six months. The AE37 vaccine is a combination of a fragment of the HER2 protein plus a proprietary modification developed by Antigen Express scientists.
nitial initial;"> @ ASCO 2013 .The presentation entitled "Booster inoculations of the AE37 peptide vaccine enhance immunological responses in a phase II study", by Eleftheria Anastasopoulou et al, demonstrates that increased immunological responses observed after the initial series of inoculations with AE37 can be further increased over a 24 month period in patients receiving boosters every six months. The AE37 vaccine is a combination of a fragment of the HER2 protein plus a proprietary modification developed by Antigen Express scientists.
initial;"> @ ASCO 2013 .The presentation entitled "Booster inoculations of the AE37 peptide vaccine enhance immunological responses in a phase II study", by Eleftheria Anastasopoulou et al, demonstrates that increased immunological responses observed after the initial series of inoculations with AE37 can be further increased over a 24 month period in patients receiving boosters every six months. The AE37 vaccine is a combination of a fragment of the HER2 protein plus a proprietary modification developed by Antigen Express scientists.
al;"> @ ASCO 2013 .The presentation entitled "Booster inoculations of the AE37 peptide vaccine enhance immunological responses in a phase II study", by Eleftheria Anastasopoulou et al, demonstrates that increased immunological responses observed after the initial series of inoculations with AE37 can be further increased over a 24 month period in patients receiving boosters every six months. The AE37 vaccine is a combination of a fragment of the HER2 protein plus a proprietary modification developed by Antigen Express scientists.
@ ASCO 2013 .The presentation entitled "Booster inoculations of the AE37 peptide vaccine enhance immunological responses in a phase II study", by Eleftheria Anastasopoulou et al, demonstrates that increased immunological responses observed after the initial series of inoculations with AE37 can be further increased over a 24 month period in patients receiving boosters every six months. The AE37 vaccine is a combination of a fragment of the HER2 protein plus a proprietary modification developed by Antigen Express scientists.
O 2013 .The presentation entitled "Booster inoculations of the AE37 peptide vaccine enhance immunological responses in a phase II study", by Eleftheria Anastasopoulou et al, demonstrates that increased immunological responses observed after the initial series of inoculations with AE37 can be further increased over a 24 month period in patients receiving boosters every six months. The AE37 vaccine is a combination of a fragment of the HER2 protein plus a proprietary modification developed by Antigen Express scientists.
.The presentation entitled "Booster inoculations of the AE37 peptide vaccine enhance immunological responses in a phase II study", by Eleftheria Anastasopoulou et al, demonstrates that increased immunological responses observed after the initial series of inoculations with AE37 can be further increased over a 24 month period in patients receiving boosters every six months. The AE37 vaccine is a combination of a fragment of the HER2 protein plus a proprietary modification developed by Antigen Express scientists.
span> presentation entitled "Booster inoculations of the AE37 peptide vaccine enhance immunological responses in a phase II study", by Eleftheria Anastasopoulou et al, demonstrates that increased immunological responses observed after the initial series of inoculations with AE37 can be further increased over a 24 month period in patients receiving boosters every six months. The AE37 vaccine is a combination of a fragment of the HER2 protein plus a proprietary modification developed by Antigen Express scientists.
presentation entitled "Booster inoculations of the AE37 peptide vaccine enhance immunological responses in a phase II study", by Eleftheria Anastasopoulou et al, demonstrates that increased immunological responses observed after the initial series of inoculations with AE37 can be further increased over a 24 month period in patients receiving boosters every six months. The AE37 vaccine is a combination of a fragment of the HER2 protein plus a proprietary modification developed by Antigen Express scientists.
an> presentation entitled "Booster inoculations of the AE37 peptide vaccine enhance immunological responses in a phase II study", by Eleftheria Anastasopoulou et al, demonstrates that increased immunological responses observed after the initial series of inoculations with AE37 can be further increased over a 24 month period in patients receiving boosters every six months. The AE37 vaccine is a combination of a fragment of the HER2 protein plus a proprietary modification developed by Antigen Express scientists.
/span> presentation entitled "Booster inoculations of the AE37 peptide vaccine enhance immunological responses in a phase II study", by Eleftheria Anastasopoulou et al, demonstrates that increased immunological responses observed after the initial series of inoculations with AE37 can be further increased over a 24 month period in patients receiving boosters every six months. The AE37 vaccine is a combination of a fragment of the HER2 protein plus a proprietary modification developed by Antigen Express scientists.
presentation entitled "Booster inoculations of the AE37 peptide vaccine enhance immunological responses in a phase II study", by Eleftheria Anastasopoulou et al, demonstrates that increased immunological responses observed after the initial series of inoculations with AE37 can be further increased over a 24 month period in patients receiving boosters every six months. The AE37 vaccine is a combination of a fragment of the HER2 protein plus a proprietary modification developed by Antigen Express scientists.
l="nofollow" rel="nofollow" href="
(0)
(0)Scroll down for more posts ▼